Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND1 | P24385 | 1/20 | 0.33 |
| ▸ | CCND2 | P30279 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teroxirone SCHEMBL2097375 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL4452999 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL2097151 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL4461477 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL4932 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL4472568 | 1.00 | TP53 (1.00) | TP53HBBSMN1; SMN2DHFRMAPT | |
| SCHEMBL10963410 | 0.93 | TP53 (0.86) | TP53HBBSMN1; SMN2DHFRMAPT | |
| SCHEMBL17804388 | 0.89 | TP53 (0.78) | TP53HBBSMN1; SMN2DHFRMAPT | |
| Teroxirone SCHEMBL10993252 | 0.89 | TP53 (0.78) | TP53HBBSMN1; SMN2DHFRMAPT | |
| SCHEMBL1715098 | 0.89 | TP53 (0.78) | TP53HBBSMN1; SMN2DHFRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1375498-B1 | Optically active epoxy compound | NISSAN CHEMICAL IND LTD (JP) | 2013-01-09 | — | — | EP | claimed |
| EP-2138491-A1 | Optically active epoxy compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-12-30 | — | — | EP | claimed |
| EP-1375498-A1 | Optically active epoxy compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2004-01-02 | — | — | EP | claimed |
| US-6641784-B1 | Optically active isocyanurate and optical resolver comprising derivative of the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-04 | — | — | US | claimed |
| EP-1061080-B1 | OPTICALLY ACTIVE EPOXY COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2003-09-24 | — | — | EP | claimed |
| US-6605717-B2 | (2R,2'R,2''R)-tris-(2,3-epoxypropyl)-isocyanurate or (2S,2'S,2''S)-tris-(2,3-epoxypropyl)-isocyanurate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | claimed |
| US-6444814-B1 | REACTING EPICHLOROHYDRIN AND ISOCYANURIC ACID | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2002-09-03 | — | — | US | claimed |
| US-20020111485-A1 | Optically active epoxy compound | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2002-08-15 | — | — | US | claimed |
| EP-1061080-A1 | OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2000-12-20 | — | — | EP | claimed |
| US-20150353684-A1 | HIGHLY SOLUBLE TRIS- (2, 3-EPOXYPROPYL)- ISOCYANURATE AND METHOD FOR PRODUCING SAME | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-10 | — | — | US | disclosed |
| EP-1375498-B1 | Optically active epoxy compound | NISSAN CHEMICAL IND LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-2138491-A1 | Optically active epoxy compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-12-30 | — | — | EP | disclosed |
| EP-1227094-B1 | Isocyanurate compound and method for producing the same | NISSAN CHEMICAL IND LTD (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-6903212-B2 | Method for reducing an organic solvent remaining in β-form tris- (2,3,-epoxypropyl)—isocyanurate crystals | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20010018517-A1 | Method for reducing organic solvents remaining in tris-(2,3-epoxypropyl)-isocyanurate crystals | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-08-30 | — | — | US | disclosed |
| EP-1061080-A1 | OPTICALLY ACTIVE EPOXY COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-6124454-A | β-form tris-(2, 3-epoxypropyl)-isocyanurate crystals and process for their production | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-26 | — | — | US | disclosed |
| US-6111104-A | PULVERIZING THE SOLVENT-WASHED CRYSTAL PARTICLES WHILE EVAPORATING SOLVENT AND EPICHLOROHYDRIN REACTANT FROM THE SURFACES OF THE PARTICLES, E.G. MACHINE PULVERIZATION IN A GAS STREAM. | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0984011-A1 | Method for reducing an organic solvent remaining in tris-(2,3-expoxy-propyl)-isocyanurate crystals | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 2000-03-08 | — | — | EP | disclosed |
| EP-0952155-A1 | Beta-form tris-(2,3-epoxypropyl)-isocyanurate crystals and process for their production | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111485-A1 | Optically active epoxy compound | TREH, APEH, EPHX2 | TP53 4731/4885HBB 441/4885SMN1; SMN2 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.